Raymond James Financial Services Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Raymond James Financial Services Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,396	Closed	-$491K	–	3394
2023 Q1	$491K	Buy	+5,396	New	+$317K	﹤0.01%	2358
2021 Q4	–	Sell	-2,458	Closed	-$247K	–	3468
2021 Q3	$247K	Buy	2,458 +206	+9%	+$24.1K	﹤0.01%	2829
2021 Q2	$319K	Sell	2,252 -399	-15%	-$45.1K	﹤0.01%	2675
2021 Q1	$264K	Buy	2,651 +850	+47%	+$99.1K	﹤0.01%	2713
2020 Q4	$223K	Buy	+1,801	New	+$237K	﹤0.01%	2649
2020 Q3	–	Sell	-2,175	Closed	-$339K	–	3021
2020 Q2	$339K	Buy	+2,175	New	+$331K	﹤0.01%	2163

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial Services Advisors's RETA Position: Q2 2023 in Review

Raymond James Financial Services Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 5,396 shares — an estimated $491K sold.

Raymond James Financial Services Advisors first reported a position in RETA in Q2 2020 and held it in 6 quarters. The position peaked at $491K in Q1 2023. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

Raymond James Financial Services Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Raymond James Financial Services Advisors sold 5,396 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $491K.
Raymond James Financial Services Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2020 and held it in 6 quarters.
Raymond James Financial Services Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $491K in Q1 2023.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2023, filed 25 Jul 2023.